ImageneBio is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune, and inflammatory diseases with differentiated clinical profiles. The company’s program, IMG-007, is a receptor targeting, nondepleting anti-OX40 monoclonal antibody with multiple differentiating features. Imagene has completed Phase 1b/2a clinical trials of IMG-007 in both atopic dermatitis and alopecia areata and is currently conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.

ImageneBio

Kristin Yarema

This department oversees the planning, execution, and management of clinical trials and operations to ensure compliance and efficiency in research processes.

Clinical Operations

This department oversees the overall strategy and direction of the organization, ensuring alignment across all functions.

Executive Leadership

This department oversees financial management and human resources functions to support organizational growth.

Finance and HR

This department manages and oversees the research and development processes for clinical programs.

Clinical Development

This department focuses on cultivating and advancing leadership skills within the organization.

ImageneBio

Org chart

Teams

Clinical Operations

Executive Leadership

Finance and HR

Clinical Development

Leadership Development

Offices

ImageneBio

Org chart

Teams

Clinical Operations

Executive Leadership

Finance and HR

Clinical Development

Leadership Development

Offices

Related companies